Adaptive Biotechnologies Corp (ADPT)
↓ Download CSV- Sector Manufacturing
- Incorporated WA
- Fiscal year ends Dec 31
In fiscal 2025, Adaptive Biotechnologies Corp reported revenue of $276.98M, up 54.8% from the prior year. The company ran a net loss, with a net margin of -21.5%. It held $512.74M in total assets against $287.74M in total liabilities.
Key ratios (FY2025)
-20.6%
Operating margin
-21.5%
Net margin
-27.2%
Return on equity
+54.8%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $276.98M | $178.96M | $170.28M | $185.31M | $154.34M | $98.38M | $85.07M | $55.66M | $38.45M | — |
| Cost of Revenue | $71.36M | $72.08M | $75.55M | $57.91M | $49.30M | $22.53M | $22.27M | $19.67M | $15.68M | — |
| Operating Income | -$57.12M | -$162.55M | -$227.03M | -$200.19M | -$208.97M | -$152.82M | -$78.39M | -$49.76M | -$44.48M | — |
| Net Income | -$59.50M | -$159.49M | -$225.25M | -$200.19M | -$207.28M | -$146.23M | -$68.61M | -$46.45M | -$42.83M | — |
| EPS (Diluted) | $-0.39 | $-1.08 | $-1.56 | $-1.40 | $-1.48 | $-1.11 | — | — | — | — |
| Total Assets | $512.74M | $539.38M | $661.13M | $856.62M | $923.34M | $1.12B | $912.30M | $332.69M | — | — |
| Total Liabilities | $287.74M | $336.89M | $352.86M | $392.52M | $319.24M | $373.15M | $341.26M | $29.94M | — | — |
| Shareholders' Equity | $218.79M | $202.71M | $308.40M | $464.17M | $603.99M | $743.27M | $571.04M | -$258.11M | -$224.62M | -$189.73M |
| Cash & Equivalents | $70.50M | $47.92M | $65.06M | $90.03M | $139.06M | $123.44M | $96.58M | $55.03M | — | — |
| Operating Cash Flow | -$45.99M | -$95.21M | -$156.32M | -$183.94M | -$192.73M | -$149.68M | $205.40M | -$32.26M | -$34.86M | — |
| Capital Expenditures | $2.96M | $3.66M | $10.70M | $16.35M | $61.75M | $18.80M | $11.20M | $6.30M | $2.42M | — |
| Shares Outstanding | 153.78M | 147.77M | 145.08M | 143.11M | 141.39M | 137.65M | 125.24M | 12.84M | — | — |